No Data
No Data
Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations
Thursday, Halloween Market Falls in Scary Reaction to Earnings | Wall Street Today
Express News | Regeneron Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
Eylea Headwinds Said to Be Behind Regeneron's Post-Q3 Plunge
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,150
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,215
No Data
No Data